Meridian Bioscience (VIVO) Misses Q4 EPS by 1c

Meridian Bioscience (NASDAQ: VIVO) reported Q4 EPS of $0.20, $0.01 worse than the analyst estimate of $0.21. Revenue for the quarter came in at $47.1 million versus the consensus estimate of $46.6 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• Vislink Technologies Inc. (VISL) Misses Q2 EPS by 7c
• VivoPower Approves Independent Listing of 2.2GW Non-Nordic AI Infrastructure Platform, Transferring Capital Expenditure Requirements Whilst Retaining De Facto Control